Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
15 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
16 Mar 22
Current reports
8-K
Regulation FD Disclosure
23 Apr 24
8-K
Regulation FD Disclosure
22 Apr 24
8-K
Regulation FD Disclosure
16 Apr 24
8-K
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
25 Mar 24
8-K
Regulation FD Disclosure
7 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
13 Nov 23
8-K
Regulation FD Disclosure
23 Oct 23
8-K
Regulation FD Disclosure
17 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
3 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
5 Dec 22
POS AM
Prospectus update (post-effective amendment)
5 Dec 22
S-8
Registration of securities for employees
17 Oct 22
424B3
Prospectus supplement
16 Sep 22
S-3
Shelf registration
6 Sep 22
D
$3M in equity / securities to be acquired, sold $3M, 1 investor
3 Aug 22
D
$1.47M in equity, sold $1.47M, 4 investors
21 Mar 22
424B3
Prospectus supplement
3 Nov 21
S-3
Shelf registration
22 Oct 21
S-3
Shelf registration
3 May 21
Proxies
DEFR14A
Revised proxy
16 Aug 23
DEF 14A
Definitive proxy
14 Aug 23
DEF 14A
Definitive proxy
16 Aug 22
DEFA14A
Additional proxy soliciting materials
11 Aug 22
PRE 14A
Preliminary proxy
3 Aug 22
DEFA14A
Additional proxy soliciting materials
1 Aug 22
DEFA14A
Additional proxy soliciting materials
6 Oct 21
DEFA14A
Additional proxy soliciting materials
21 Sep 21
DEFR14A
Revised proxy
25 Aug 21
DEFR14A
Revised proxy
17 Aug 21
Other
EFFECT
Notice of effectiveness
9 Dec 22
EFFECT
Notice of effectiveness
15 Sep 22
CORRESP
Correspondence with SEC
12 Sep 22
UPLOAD
Letter from SEC
9 Sep 22
EFFECT
Notice of effectiveness
3 Nov 21
UPLOAD
Letter from SEC
29 Oct 21
CORRESP
Correspondence with SEC
29 Oct 21
EFFECT
Notice of effectiveness
12 May 21
CORRESP
Correspondence with SEC
7 May 21
UPLOAD
Letter from SEC
7 May 21
Ownership
4
STEVEN A SHALLCROSS
15 Dec 23
4
Jeffrey Alan Wolf
15 Dec 23
4
Jeffrey J Kraws
15 Dec 23
4
JOHN J MONAHAN
15 Dec 23
4
STEVEN A SHALLCROSS
8 Jun 23
4
STEVEN A SHALLCROSS
7 Jun 23
4
STEVEN A SHALLCROSS
13 Feb 23
4
STEVEN A SHALLCROSS
3 Feb 23
4
STEVEN A SHALLCROSS
26 Jan 23
4
STEVEN A SHALLCROSS
23 Jan 23